全部照片(1)
About This Item
經驗公式（希爾表示法）:
C21H33N3O5S
CAS號碼:
分子量：:
439.57
EC號碼:
MDL號碼:
分類程式碼代碼:
51111800
PubChem物質ID:
NACRES:
NA.77
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D +215 to +245°, c = 1 in ethanol
顏色
white to beige
溶解度
DMSO: 5 mg/mL, clear (warmed)
儲存溫度
−20°C
SMILES 字串
CC1(C)[C@H](C(OCOC(C(C)(C)C)=O)=O)N2C([C@](/N=C/N3CCCCCC3)([H])[C@@]2([H])S1)=O
InChI
1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/b22-12+/t14-,15+,17-/m1/s1
InChI 密鑰
NPGNOVNWUSPMDP-UTEPHESZSA-N
應用
Pivmecillinam has been used to test its efficacy as a breast cancer stem cells (CSCs) targeting agent.
生化／生理作用
Pivmecillinam is a β-lactam antibiotic and a pivaloyl-containing pro-drug. It belongs to the class of amidinopenicillin. Pivmecillinam is an oral anti-microbial agent that can be considered for treating E. coli urinary tract infection (UTI).
Pivmecillinam is a gram negative antibiotic, and inhibitor of penicillin-binding protein 2 (PBP2).
Pivmecillinam is a gram negative antibiotic, and inhibitor of penicillin-binding protein 2 (PBP2). Pivmecillinam has been shown to have synergistic effects with several antibiotics including novobiocin and rifampin in gram negative bacteria.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Beatrix S Traa et al.
International journal of epidemiology, 39 Suppl 1, i70-i74 (2010-04-02)
Ciprofloxacin, ceftriaxone and pivmecillinam are the antibiotics currently recommended by the World Health Organization (WHO) for the treatment of dysentery in children; yet there have been no reviews of the clinical effectiveness of these antibiotics in recent years. We reviewed
Sven A Ferry et al.
Scandinavian journal of infectious diseases, 36(4), 296-301 (2004-06-17)
This prospective, multicentre, randomized, double-blind and placebo controlled study was performed to describe the natural course of uncomplicated lower urinary tract infection (UTI). A total of 1143 women 18 y and above, consulting at 18 primary health care centres in
Mette Nørgaard et al.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 116(4), 278-283 (2008-04-10)
Few data exist on the risk of miscarriage after exposure to pivmecillinam. We therefore conducted a population-based case-control study in a Danish county with 0.5 million inhabitants during the period 1997-2002. We included 1,599 women with a miscarriage recorded in
Lindsay E Nicolle et al.
Scandinavian journal of infectious diseases, 39(8), 748-749 (2007-07-27)
Oral therapy options for pyelonephritis caused by ESBL producing E. coli are limited. We describe a woman with relapsing pyelonephritis due to a CTX-M ESBL E. coli who was cured with a prolonged course of pivmecillinam. This suggests pivmecillinam may
Birgit Stattin Norinder et al.
Antimicrobial agents and chemotherapy, 50(4), 1528-1530 (2006-03-30)
Similar changes in the periurethral and vaginal microflora were observed in 19 women with recurrent urinary tract infection following treatment with norfloxacin (NOR) or pivmecillinam (PIV). Escherichia coli strains were suppressed by both treatments. Staphylococcus spp. and enterococci colony counts
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務